APA (7th ed.) Citation

Palandri, F., Schaap, N. P. M., Rey, J., von Bubnoff, N., Reiter, A., Hernandez-Boluda, J. C., . . . Oh, S. T. (2026). Spleen volume reduction and transfusion independence with momelotinib versus ruxolitinib and associated overall survival with momelotinib in JAK inhibitor-naive patients with myelofibrosis and anemia: Subgroup analyses of SIMPLIFY-1. Clinical lymphoma, myeloma & leukemia, 26(5), . https://doi.org/10.1016/j.clml.2026.02.004

Chicago Style (17th ed.) Citation

Palandri, Francesca, et al. "Spleen Volume Reduction and Transfusion Independence with Momelotinib Versus Ruxolitinib and Associated Overall Survival with Momelotinib in JAK Inhibitor-naive Patients with Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1." Clinical Lymphoma, Myeloma & Leukemia 26, no. 5 (2026). https://doi.org/10.1016/j.clml.2026.02.004.

MLA (9th ed.) Citation

Palandri, Francesca, et al. "Spleen Volume Reduction and Transfusion Independence with Momelotinib Versus Ruxolitinib and Associated Overall Survival with Momelotinib in JAK Inhibitor-naive Patients with Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1." Clinical Lymphoma, Myeloma & Leukemia, vol. 26, no. 5, 2026, https://doi.org/10.1016/j.clml.2026.02.004.